Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5.1MCash on Hand
10.4mo Cash Runway
Follow TRIB by emailGet an email when TRIB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TRIB, unsubscribe in one click. Privacy
📣 What TRIB Says Is Next
in 2026 · “The data center liquid cooling market is developing rapidly and projected by third-party industry research to grow from approximately $4 billion in 2026 to $27 billion by 2033. 1 Direct-to-chip liquid cooling is a thermal-management approach that brings coolant closer to high-performance processors and other heat-generating components.”
Company press release, Sep 9, 2026 · SEC filing
in 2026 · “According to MarketsandMarkets, the data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, representing a 31.5% CAGR 2 .”
Company press release, Jun 30, 2026 · SEC filing
in 2026 · “The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, representing a 31.5% CAGR (2026, MarketsandMarkets) 2 , driven by increasing AI compute density and the growing adoption of liquid-cooled infrastructure.”
Company press release, Jun 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Financing Trinity Biotech amended its credit agreement with Perceptive Credit Holdings III, LP, providing about $9.5 million of total investment ($4.0 million new debt and $5.5 million capitalized interest) and waiving Minimum Liquidity Covenant breaches for June through October 2026. Form 6-K · SEC filing · Press release
Oct 5, 2026 ·
Shareholder vote Trinity Biotech shareholders approved all resolutions at the September 30, 2026 annual general meeting, with each receiving at least 95% of votes cast. Items included re-appointing Grant Thornton as auditor, authorizing the board to fix auditor remuneration, and re-appointing Dr Andrew Omidvar as a director. Form 6-K · SEC filing
Sep 9, 2026 ·
Deal Trinovium, Trinity Biotech's cooling unit, signed a contract with Red Team Investments to supply advanced fluids and analytical systems for a U.S. commercial pilot in AI and high-performance computing data centers. No payment amounts were disclosed. Form 6-K · SEC filing · Press release
Sep 8, 2026 ·
Shareholder vote Trinity Biotech furnished its 2025 Annual Report and sent shareholders notice of its September 30, 2026 AGM, where holders will vote on reappointing Grant Thornton as auditor, setting auditor pay, and re-electing director Andrew Omidvar. Co-founder Ronan O'Caoimh has left the board. Form 6-K · SEC filing · Press release
Aug 28, 2026 ·
Listing Trinity Biotech hired Jordi Romero as Head of Commercial Operations, Europe, and completed rollout of its upgraded HbA1c column system in three large international markets. It received a European patent for PrePsia, bringing its total to nine granted U.S. and European patents. Form 6-K · SEC filing · Press release
Aug 17, 2026 ·
Deal Trinovium, Trinity Biotech's subsidiary, agreed to a strategic collaboration with Echelon Data Centres to develop direct-to-chip liquid cooling fluids, thermal management systems and modular cooling solutions for AI infrastructure. No financial terms were disclosed. Form 6-K · SEC filing · Press release
Aug 14, 2026 ·
Financing Perceptive Advisors-affiliated lenders agreed to a credit amendment providing about $7.0 million, including $2.5 million of new debt and $4.5 million of capitalized interest. Nasdaq confirmed regained compliance with the minimum bid price rule on August 7, 2026. Preliminary Q2 2026 revenue was about $10.5 million. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2028 · N/A · Recruiting · Lifewise Preventive Video Education in Primary Care Registry primary completion date, not a results date
Apr 2026 · N/A · Active Trial · Evaluation of an Adolescent Pregnancy Prevention Program; Relationship Smarts+ With Lessons From Mind Matters Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TRIB holds $5.1M in cash and short-term investments and burns about $1.5M/quarter from operations,
an estimated runway of 10.4 months at that rate (BioRadar estimate, not company guidance).
Share count 374,206,640 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TRIB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRIB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.